{"schema_version":"secwatch.filing_event.v1","accession":"0001846253-23-000024","form_type":"8-K","ticker":"OABI","cik":"0001846253","company_name":"OmniAb, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.103744+00:00","generated_at":"2026-06-17T09:41:19.846406+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OmniAb Q4 revenue $35.3M, net income $6.8M; record 13 new partnerships in 2022","bullets":["Q4 revenue $35.3M (up from $15.3M YoY) driven by $25M TECVAYLI milestone; net income $6.8M vs loss of $3.1M.","Full year 2022 revenue $59.1M (up from $34.7M); net loss $22.3M ($0.26/share) vs $27.0M loss in 2021.","Cash and short-term investments $88.3M at Dec 31, 2022; received additional $35M in Jan 2023 from Janssen.","Signed 13 new licenses in 2022; 26 OmniAb-derived programs in clinic/commercial; 291 total programs.","Expects $10M milestone from TECVAYLI EU approval in 2023; 2023 year-end cash slightly higher than 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001846253-23-000024","json":"https://secwatch.observer/filing/0001846253-23-000024.json","markdown":"https://secwatch.observer/filing/0001846253-23-000024.md","text":"https://secwatch.observer/filing/0001846253-23-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1846253/000184625323000024/0001846253-23-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1846253/000184625323000024/lgnd-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:41:19.846406+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3137ad6c3ed4a70c505dba42fddbd1feff371886","claim":"OmniAb, Inc. reported financial results for three months and full year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, OmniAb Incorporated (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1846253/000184625323000024/0001846253-23-000024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}